These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 2952510

  • 1. Deficient tumor-specific immunity in old mice: in vivo mediation by suppressor cells, and correction of the defect by interleukin 2 supplementation in vitro but not in vivo.
    Bruley-Rosset M, Payelle B.
    Eur J Immunol; 1987 Mar; 17(3):307-12. PubMed ID: 2952510
    [Abstract] [Full Text] [Related]

  • 2. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD.
    Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S, Yamamoto H, Fujii Y, Arai S.
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [Abstract] [Full Text] [Related]

  • 4. [T-suppressors from tumor-bearing mice inhibit antitumor cytotoxic T-lymphocytes in monoculture].
    Lupatov AIu, Brondz BD.
    Biull Eksp Biol Med; 1992 Feb; 113(2):186-7. PubMed ID: 1535235
    [Abstract] [Full Text] [Related]

  • 5. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
    Li T, Harada M, Tamada K, Abe K, Nomoto K.
    Anticancer Res; 1997 Feb; 17(6D):4259-68. PubMed ID: 9494518
    [Abstract] [Full Text] [Related]

  • 6. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
    Fujii T, Igarashi T, Kishimoto S.
    J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
    [Abstract] [Full Text] [Related]

  • 7. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.
    Shu SY, Chou T, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):295-304. PubMed ID: 2953816
    [Abstract] [Full Text] [Related]

  • 8. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M, Argentati K, Tibaldi A.
    Gene Ther; 2000 Apr 01; 7(7):624-32. PubMed ID: 10819579
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro T cell-mediated killing of Pseudomonas aeruginosa. V. Generation of bactericidal T cells in nonresponder mice.
    Powderly WG, Pier GB, Markham RB.
    J Immunol; 1987 Apr 01; 138(7):2272-7. PubMed ID: 2951437
    [Abstract] [Full Text] [Related]

  • 17. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H, Chang AE, Shu S.
    J Immunol; 1991 Jul 15; 147(2):729-37. PubMed ID: 1830072
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.
    Chen W, Reese VA, Cheever MA.
    J Immunol; 1990 May 15; 144(10):3659-66. PubMed ID: 2332628
    [Abstract] [Full Text] [Related]

  • 20. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.
    Shu S, Chou T, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3891-8. PubMed ID: 3486223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.